Climb Bio, Inc. entered into an Open Market Sale Agreement with Jefferies LLC to offer and sell up to $100.0 million in common stock via an at-the-market offering. Additionally, the company terminated its previous $22.35 million Equity Distribution Agreement with Oppenheimer & Co. Inc. effective June 11, 2026, without incurring any termination penalties. Climb Bio, Inc. is a biotechnology company focused on developing and commercializing therapeutic solutions.
